Lonza Welcomes Healthy Future for Brazilian Dietary Supplements Market at Fi South America
Alessandro Hinrichsen, Latin America Business Unit Lead, Lonza Consumer Health & Nutrition:
“The dietary supplements market in Brazil is predicted to reach annual sales of an estimated USD 1 billion by 2023. Now, lifestyle choices such as the decision to follow a vegetarian or vegan diet, as well as the rising popularity of gluten-free products, are also shaping the future of the industry.
“According to Euromonitor, demand for combination supplement products is also expected to rise among Brazilian consumers. Our DUOCAP® capsule-in-capsule delivery system is the ideal solution for manufacturers looking to formulate with ingredients that have previously been incompatible or have different release profiles.”
Rio de Janeiro (BR), 09 August 2019–– Lonza brings a carnival of color to this year’s Fi South America, with the industry’s first clean-label colored capsules now available to dietary supplement manufacturers in Brazil. Thanks to the latest innovations in coloring foods, the Vcaps® Plus Purple Carrot and Blue Spirulina capsules open new possibilities for Lonza’s customers to create bright, vibrant products without compromising on a natural positioning. At booth 6-80 Lonza will also present its portfolio of scientifically-backed ingredients for sports nutrition and other high growth market segments, including the healthy living trend which continues to gain traction in Brazil.
“The dietary supplements market in Brazil is predicted to reach annual sales of an estimated USD 1 billion by 2023. Now, lifestyle choices such as the decision to follow a vegetarian or vegan diet, as well as the rising popularity of gluten-free products, are also shaping the future of the industry,” comments Alessandro Hinrichsen, Latin America Business Unit Lead, Lonza Consumer Health & Nutrition.
Advanced Capsule Technologies
Lonza’s market-leading portfolio of high-quality, vegetarian capsules enables its customers to overcome labelling requirements and formulation and delivery challenges associated with clean label supplements. Products in its plant-based range include DRcaps™ capsules for the timed release of active ingredients, alongside its high-performance Vcaps® Plus capsules made from hypromellose (HPMC) and water only.
“According to Euromonitor, demand for combination supplement products is expected to rise among Brazilian consumers. Our DUOCAP® capsule-in-capsule delivery system is the ideal solution for manufacturers looking to formulate with ingredients that have previously been incompatible or have different release profiles,” adds Alessandro Hinrichsen.
Healthy Living Trend
Brazilian consumers are increasingly looking to dietary supplements to address concerns related to aging well and the desire to maintain healthy, active lives for longer. Lonza’s extensive health and nutrition portfolio features several clinically studied ingredients that address the latest consumer demands, including UC-II® undenatured type II collagen, as well as Lonza’s proprietary ResistAid® ingredient. Its Carnipure® L-Carnitine brand offers benefits in a range of high-growth market segments, including sports nutrition, and is backed by more than 30 years of experience and 45 clinical trials.
Visitors can book an appointment here to meet with the expert team from Lonza Consumer Health & Nutrition at booth 6-80 at Fi South America, or find out more information at www.lonza.com.
About Lonza
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.
Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.
Lonza Contact Details
Dr. Kristin Koehler
Investor Relations
Lonza Group Ltd
Tel +41 61 316 8782
kristin.koehler@lonza.com
Dr Sanna Fowler
Head of Public Relations
Lonza Pharma & Biotech
Tel +41 61 316 8929
sanna.fowler@lonza.com